Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 4/2014

01-08-2014

Translational suppression of HIF-1α by miconazole through the mTOR signaling pathway

Authors: Jee-Young Park, Hui-Jung Jung, Incheol Seo, Bijay Kumar Jha, Seong-Il Suh, Min-Ho Suh, Won-Ki Baek

Published in: Cellular Oncology | Issue 4/2014

Login to get access

Abstract

Background

Miconazole is an imidazole antifungal agent that has amply been used in the treatment of superficial mycosis. Preliminary data indicate that miconazole may also induce anticancer effects. As yet, however, little is known about the therapeutic efficacy of miconazole on cancer and the putative mechanism(s) involved. Here, we show that miconazole suppresses hypoxia inducible factor-1α (HIF-1α) protein translation in different cancer-derived cells.

Methods

The effect of miconazole on HIF-1α expression was examined by Western blotting and reverse transcriptase polymerase chain reaction assays in human U87MG and MCF-7 glioma and breast cancer-derived cell lines, respectively. The transcriptional activity of the HIF-1 complex was confirmed using a luciferase assay. To assess whether angiogenic factors are increased under hypoxic conditions in these cells, vascular endothelial growth factor (VEGF) levels were measured by ELISA. Metabolic labeling was performed to examine HIF-1α protein translation and global protein synthesis. The role of the mammalian target of rapamycin (mTOR) signaling pathway was examined to determine translation regulation of HIF-1α after miconazole treatment.

Results

Miconazole was found to suppress HIF-1α protein expression through post-transcriptional regulation in U87MG and MCF-7 cells. The suppressive effect of HIF-1α protein synthesis was found to be due to inhibition of mTOR. Miconazole significantly inhibited the transcriptional activity of the HIF-1 complex and the expression of its target VEGF. Moreover, miconazole was found to suppress global protein synthesis by inducing phosphorylation of the translation initiation factor 2α (eIF2α).

Conclusion

Our data indicate that miconazole plays a role in translational suppression of HIF-1α. We suggest that miconazole may represent a novel therapeutic option for the treatment of cancer.
Literature
1.
J.J. Lou, Y.L. Chua, E.H. Chew, J. Gao, M. Bushell, T. Hagen, Inhibition of hypoxia-inducible factor-1 alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents. PLoS One 5, e10522 (2010)PubMedCentralPubMedCrossRef
2.
3.
4.
W.G. Kaelin Jr., The von Hippel-Lindau tumour suppressor protein: O2sensing and cancer. Nat. Rev. Cancer 8, 865–873 (2008)PubMedCrossRef
5.
N. Masson, C. Willam, P.H. Maxwell, C.W. Pugh, P.J. Ratcliffe, Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 20, 5197–5206 (2001)PubMedCentralPubMedCrossRef
6.
D.J. Manalo, A. Rowan, T. Lavoie, L. Natarajan, B.D. Kelly, S.Q. Ye, J.G. Garcia, G.L. Semenza, Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105, 659–669 (2005)PubMedCrossRef
7.
C.D. Young, A.S. Lewis, M.C. Rudolph, M.D. Ruehle, M.R. Jackman, U.J. Yun, O. Ilkun, R. Pereira, E.D. Abel, S.M. Anderson, Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One 6, e23205 (2011)PubMedCentralPubMedCrossRef
8.
N. Shaida, R. Launchbury, J.L. Boddy, C. Jones, L. Campo, H. Turley, S. Kanga, A.H. Banham, P.R. Malone, A.L. Harris, S.B. Fox, Expression of BNIP3 correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines. Prostate 68, 336–343 (2008)PubMedCrossRef
9.
H. Bando, T. Atsumi, T. Nishio, H. Niwa, S. Mishima, C. Shimizu, N. Yoshioka, R. Bucala, T. Koike, Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin. Cancer Res. 11, 5784–5792 (2005)PubMedCrossRef
10.
G.E. Piérard, T. Hermanns-Lê, P. Delvenne, C. Piérard-Franchimont, Miconazole, a pharmacological barrier to skin fungal infections. Expert. Opin. Pharmacother. 13, 1187–1194 (2012)PubMedCrossRef
11.
H.T. Chang, W.C. Chen, J.S. Chen, Y.C. Lu, S.S. Hsu, J.L. Wang, H.H. Cheng, J.S. Cheng, B.P. Jiann, A.J. Chiang, J.K. Huang, C.R. Jan, Effect of miconazole on intracellular Ca2+ levels and proliferation in human osteosarcoma cells. Life Sci. 76, 2091–2101 (2005)PubMedCrossRef
12.
D. Zagorac, D. Jakovcevic, D. Gebremedhin, D.R. Harder, Antiangiogenic effect of inhibitors of cytochrome P450 on rats with glioblastoma multiforme. J. Cereb. Blood Flow Metab. 28, 1431–1439 (2008)PubMedCentralPubMedCrossRef
13.
C.H. Wu, J.H. Jeng, Y.J. Wang, C.J. Tseng, Y.C. Liang, C.H. Chen, H.M. Lee, J.K. Lin, C.H. Lin, S.Y. Lin, C.P. Li, Y.S. Ho, Antitumor effects of miconazole on human colon carcinoma xenografts in nude mice through induction of apoptosis and G0/G1 cell cycle arrest. Toxicol. Appl. Pharmacol. 180, 22–35 (2002)PubMedCrossRef
14.
M. Bi, C. Naczki, M. Koritzinsky, D. Fels, J. Blais, N. Hu, H. Harding, I. Novoa, M. Varia, J. Raleigh, D. Scheuner, R.J. Kaufman, J. Bell, D. Ron, B.G. Wouters, C. Koumenis, ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J. 24, 3470–3481 (2005)PubMedCentralPubMedCrossRef
15.
H.J. Jung, S.I. Suh, M.H. Suh, W.K. Baek, J.W. Park, Pentamidine reduces expression of hypoxia-inducible factor-1α in DU145 and MDA-MB-231 cancer cells. Cancer Lett. 303, 39–46 (2011)PubMedCrossRef
16.
A. Rapisarda, B. Uranchimeg, D.A. Scudiero, M. Selby, E.A. Sausville, R.H. Shoemaker, G. Melillo, Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62, 4316–4324 (2002)PubMed
17.
K.L. Talks, H. Turley, K.C. Gatter, P.H. Maxwell, C.W. Pugh, P.J. Ratcliffe, A.L. Harris, The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157, 411–421 (2000)PubMedCentralPubMedCrossRef
18.
J. Du, R. Xu, Z. Hu, Y. Tian, Y. Zhu, L. Gu, L. Zhou, PI3K and ERK-induced Rac1 activation mediates hypoxia-induced HIF-1α expression in MCF-7 breast cancer cells. PLoS One 6, e25213 (2011)PubMedCentralPubMedCrossRef
19.
C. Ercan, J.F. Vermeulen, L. Hoefnagel, P. Bult, P. van der Groep, E. van der Wall, P.J. van Diest, HIF-1α and NOTCH signaling in ductal and lobular carcinomas of the breast. Cell. Oncol. 35, 435–442 (2012)CrossRef
20.
M. Yee Koh, T.R. Spivak-Kroizman, G. Powis, HIF-1 regulation: not so easy come, easy go. Trends Biochem. Sci. 33, 526–534 (2008)PubMedCrossRef
21.
D.B. Shackelford, D.S. Vasquez, J. Corbeil, S. Wu, M. Leblanc, C.L. Wu, D.R. Vera, R.J. Shaw, mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. U. S. A. 106, 11137–11142 (2009)PubMedCentralPubMedCrossRef
22.
D.C. Fingar, C.J. Richardson, A.R. Tee, L. Cheatham, C. Tsou, J. Blenis, mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 24, 200–216 (2004)PubMedCentralPubMedCrossRef
23.
F.H. Pham, P.H. Sugden, A. Clerk, Regulation of protein kinase B and 4E-BP1 by oxidative stress in cardiac myocytes. Circ. Res. 86, 1252–1258 (2000)PubMedCrossRef
24.
R.C. Wek, H.Y. Jiang, T.G. Anthony, Coping with stress: eIF2 kinases and translational control. Biochem. Soc. Trans. 34, 7–11 (2006)PubMedCrossRef
25.
A.D. Rodrigues, D.F. Lewis, C. Ioannides, D.V. Parke, Spectral and kinetic studies of the interaction of imidazole anti-fungal agents with microsomal cytochromes P-450. Xenobiotica 17, 1315–1327 (1987)PubMedCrossRef
26.
M.R. Moody, V.M. Young, M.J. Morris, S.C. Schimpff, In vitro activities of miconazole, miconazole nitrate, and ketoconazole alone and combined with rifampin against Candida spp. and Torulopsis glabrata recovered from cancer patients. Antimicrob. Agents Chemother. 17, 871–875 (1980)PubMedCentralPubMedCrossRef
27.
W.M. Jordan, G.P. Bodey, V. Rodriguez, S.J. Ketchel, J. Henney, Miconazole therapy for treatment of fungal infections in cancer patients. Antimicrob. Agents Chemother. 16, 792–797 (1979)PubMedCentralPubMedCrossRef
28.
F. Meunier-Carpentier, M. Cruciani, J. Klastersky, Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. Eur. J. Cancer Clin. Oncol. 19, 43–48 (1983)PubMedCrossRef
29.
R.A. Lubet, V.E. Steele, I. Eto, M.M. Juliana, G.J. Kelloff, C.J. Grubbs, Chemopreventive efficacy of anethole trithione, N-acetyl-L-cysteine, miconazole and phenethylisothiocyanate in the DMBA-induced rat mammary cancer model. Int. J. Cancer 72, 95–101 (1997)PubMedCrossRef
30.
H. Zhong, A.M. De Marzo, E. Laughner, M. Lim, D.A. Hilton, D. Zagzag, P. Buechler, W.B. Isaacs, G.L. Semenza, J.W. Simons, Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59, 5830–5835 (1999)PubMed
31.
T. Shibaji, M. Nagao, N. Ikeda, H. Kanehiro, M. Hisanaga, S. Ko, A. Fukumoto, Y. Nakajima, Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res. 23, 4721–4727 (2003)PubMed
32.
B. Bachtiary, M. Schindl, R. Potter, B. Dreier, T.H. Knocke, J.A. Hainfellner, R. Horvat, P. Birner, Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin. Cancer Res. 9, 2234–2240 (2003)PubMed
33.
R. Bos, P. van der Groep, A.E. Greijer, A. Shvarts, S. Meijer, H.M. Pinedo, G.L. Semenza, P.J. van Diest, E. van der Wall, Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97, 1573–1581 (2003)PubMedCrossRef
34.
G. Powis, L. Kirkpatrick, Hypoxia inducible factor-1alpha as a cancer drug target. Mol. Cancer Ther. 3, 647–654 (2004)PubMed
35.
M. Malecki, P. Kolsut, R. Proczka, Angiogenic and antiangiogenic gene therapy. Gene Ther. 12(Suppl 1), S159–S169 (2005)PubMedCrossRef
36.
37.
J.E. Rundhaug, Matrix metalloproteinases, angiogenesis, and cancer. Clin. Cancer Res. 9, 551–554 (2003)PubMed
38.
M. Medhora, J. Daniels, K. Mundey, B. Fisslthaler, R. Busse, E.R. Jacobs, D.R. Harder, Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 284, H215–H224 (2003)PubMed
39.
C. Zhang, D.R. Harder, Cerebral capillary endothelial cell mitogenesis and morphogenesis induced by astrocytic epoxyeicosatrienoic acid. Stroke 33, 2957–2964 (2002)PubMedCrossRef
40.
D.H. Munzenmaier, D.R. Harder, Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am. J. Physiol. Heart Circ. Physiol. 278, H1163–H1167 (2000)PubMed
41.
R.J. Shaw, L.C. Cantley, Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424–430 (2006)PubMedCrossRef
42.
A. Rapisarda, G. Melillo, UVC inhibits HIF-1alpha protein translation by a DNA damage- and topoisomerase I-independent pathway. Oncogene 26, 6875–6884 (2007)PubMedCrossRef
43.
E. Connolly, S. Braunstein, S. Formenti, R.J. Schneider, Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol. Cell. Biol. 26, 3955–3965 (2006)PubMedCentralPubMedCrossRef
44.
C.X. Bian, Z. Shi, Q. Meng, Y. Jiang, L.Z. Liu, B.H. Jiang, P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression. Biochem. Biophys. Res. Commun. 398, 395–399 (2010)PubMedCentralPubMedCrossRef
45.
46.
K.X. Knaup, K. Jozefowski, R. Schmidt, W.M. Bernhardt, A. Weidemann, J.S. Juergensen, C. Warnecke, K.U. Eckardt, M.S. Wiesener, Mutual regulation of hypoxia-inducible factor and mammalian target of rapamycin as a function of oxygen availability. Mol. Cancer Res. 7, 88–98 (2009)PubMedCrossRef
47.
K. Zhu, W. Chan, J. Heymach, M. Wilkinson, D.J. McConkey, Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Res. 69, 1836–1843 (2009)PubMedCrossRef
48.
C. Koumenis, C. Naczki, M. Koritzinsky, S. Rastani, A. Diehl, N. Sonenberg, A. Koromilas, B.G. Wouters, Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol. Cell. Biol. 22, 7405–7416 (2002)PubMedCentralPubMedCrossRef
Metadata
Title
Translational suppression of HIF-1α by miconazole through the mTOR signaling pathway
Authors
Jee-Young Park
Hui-Jung Jung
Incheol Seo
Bijay Kumar Jha
Seong-Il Suh
Min-Ho Suh
Won-Ki Baek
Publication date
01-08-2014
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 4/2014
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-014-0182-8

Other articles of this Issue 4/2014

Cellular Oncology 4/2014 Go to the issue

OriginalPaper

eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation

Original Paper

ARID3B expression in primary breast cancers and breast cancer-derived cell lines

Original Paper

MGMT gene silencing by promoter hypermethylation in gastric cancer in a high incidence area

Original Paper

A novel CDC73 gene mutation in an Italian family with hyperparathyroidism-jaw tumour (HPT-JT) syndrome

Original Paper

Validation of DNA promoter hypermethylation biomarkers in breast cancer — a short report

Original Paper

Identification of novel markers that outperform EpCAM in quantifying circulating tumor cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits